Capricor Therapeutics Inc (NASDAQ:CAPR)
Capricor Therapeutics Inc (NASDAQ:CAPR) shares gapped up this morning and have gained over 20% from their Friday closing price on ten times their average daily volume. CAPR stock opened at $2.65, $0.38 above Friday’s close, and moved above the $3 handle within ten minutes. Sellers then came in and pushed the price down to $2.80 before the shares resumed their upward move. At the time of the writing, 10:15 AM EST, CAPR stock is trading around the $3 once again.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company discovers, develops, and commercializes biological therapeutics for the treatment of rare disorders. Capricor’s lead drug candidate is, CAP-1002 – an “off-the-shelf” cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
On November 8, 2017, Beverly Hills, CA-based Capricor Therapeutics, Inc. (NASDAQ:CAPR) reported a Q3 2017 loss of (-$2.7). or (-$0.12) per share, on adjusted revenues of $313,000. The loss beat analyst expectations that forecasted a loss of (-$0.19) per share. The biotech firm also bested expectations in Q2 when actual earnings beat estimates by 11%.
CAPR Stock Performance
At the beginning of 2012 CAPR stock was trading above $20 before it went into a steady slide. Over the past year CAPR stock has experienced a wide range in its price. Its 52-week low is $0.63 but its 52-week high is $4.25.
Shareholders of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have lagged the market as the stock is down 7% year-to-date. However, in the past quarter, shares have risen over 114%. That strong gain is reflected in CAPR’s Relative Strength Index score of 68 – just below the level of 70 which many traders believe to be the threshold figure for an “oversold” condition.
Losses have plagued the company since 2012 when they posted a EPS of (-$0.21), followed by annual EPS losses of (-$0.85), (-$0.53), (-$0.81), and, for 2016, (-$1.01). Sales were on a positive slope from 2013 when it reported a figure of $500,000. By 2015 that number grew to $5.5 million, but declined in 2016 to $4 million.
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $CAPR and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.